Figure 2.
Conceptual representation of an application envisioned for dL5_EAK membranes in vivo. In this scenario, membranes composed of dL5_EAK and EAK16-II would be used to intercept trafficking of inflammation-associated leukocytes to lymph nodes. Antibodies conjugated with MG would be introduced at the site of inflammation to label trafficking leukocytes. Association of cells with dL5_EAK could be detected by MG fluorescence generated by binding of MG and the FAP domain.